Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (221-230 of 231) with videos related to

Pageof 24
Sort By:
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal GammopathiesLeire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, et al.
Blood|July 22, 2020
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myelomaIbai Goicoechea, Noemi Puig, Maria-Teresa Cedena, et al.
Research Square|June 12, 2025
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)Floris Chabrun, Daniel Schwartz, Susanna Gentile, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2024
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple MyelomaAina Oliver-Caldes, Marta Español-Rego, Aintzane Zabaleta, et al.
Hemasphere|May 27, 2022
The EHA Research Roadmap: Malignant Lymphoid DiseasesMartin Dreyling, Marc André, Nicola Gökbuget, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2022
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple MyelomaRosalinda Termini, David Žihala, Evangelos Terpos, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 24

Showing results (221-230 of 231) with videos related to

Sort By:
Pageof 24
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal GammopathiesLeire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, et al.
Blood|July 22, 2020
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myelomaIbai Goicoechea, Noemi Puig, Maria-Teresa Cedena, et al.
Research Square|June 12, 2025
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)Floris Chabrun, Daniel Schwartz, Susanna Gentile, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2024
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple MyelomaAina Oliver-Caldes, Marta Español-Rego, Aintzane Zabaleta, et al.
Hemasphere|May 27, 2022
The EHA Research Roadmap: Malignant Lymphoid DiseasesMartin Dreyling, Marc André, Nicola Gökbuget, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2022
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple MyelomaRosalinda Termini, David Žihala, Evangelos Terpos, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 24